Sarepta Therapeutics (SRPT) Non-Current Debt (2010 - 2026)

Sarepta Therapeutics has reported Non-Current Debt for 17 years, with the latest figure at $838.2 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Debt fell 26.37% year-over-year to $838.2 million; the trailing twelve-month figure through Mar 2026 stood at $838.2 million (down 26.37% YoY), and the FY2025 full-year result was $829.0 million, down 27.1% from the prior year.
• Non-Current Debt for Q1 2026 stood at $838.2 million, up from $829.0 million in the prior quarter.
• The five-year high for Non-Current Debt was $1.5 billion in Q4 2022, with the low at $829.0 million in Q4 2025.
• Average Non-Current Debt over 5 years is $1.2 billion, with a median of $1.1 billion recorded in 2024.
• Year-over-year, Non-Current Debt jumped 40.9% in 2022 and dropped 27.1% in 2025.
• Tracing SRPT's Non-Current Debt over 5 years: stood at $1.5 billion in 2022, then fell by 26.66% to $1.1 billion in 2023, then climbed by 0.41% to $1.1 billion in 2024, then fell by 27.1% to $829.0 million in 2025, then climbed by 1.11% to $838.2 million in 2026.
• The last three Non-Current Debt figures came in at $838.2 million (Q1 2026), $829.0 million (Q4 2025), and $1.0 billion (Q3 2025), per Business Quant data.

Peer Comparison